Phenserine (Axonyx/NIH)

Area of Science:

• Neuroscience
• Pharmacology
• Drug Development

Background:

• Alzheimer's disease (AD) is a progressive neurodegenerative disorder.
• Current AD therapies have limitations in efficacy and side effects.
• Amyloid precursor protein (APP) and beta-amyloid (Aβ) are key pathological hallmarks of AD.

Purpose of the Study:

• To investigate phenserine, a physostigmine derivative, as a potential therapeutic agent for Alzheimer's disease.
• To evaluate the safety, tolerability, and preliminary efficacy of phenserine in clinical trials.
• To assess the in vitro and in vivo effects of phenserine on Aβ production and cognitive function.

Main Methods:

• Phenserine's effects on APP and Aβ production were assessed in vitro using human neuronal cells.
• Phase I and Ib clinical trials were conducted to evaluate safety and tolerability in healthy elderly volunteers and AD patients.
• Preclinical studies in aged rats examined phenserine's effects on learning and its toxicity profile compared to physostigmine.

Main Results:

• Phenserine significantly reduced beta-amyloid peptide production by 30% in human neuronal cells in vitro.
• Phenserine demonstrated a long duration of action (t(1/2) = 8 to 10 hours).
• Preclinical studies indicated lower toxicity and some cognitive effects in aged rats compared to physostigmine.

Conclusions:

• Phenserine shows potential as a novel therapeutic for Alzheimer's disease due to its ability to reduce Aβ production and its favorable safety profile.
• Ongoing clinical trials are crucial for confirming phenserine's efficacy and safety in AD patients.
• Further research is warranted to optimize phenserine's therapeutic application in managing Alzheimer's disease.